Stem cell transplantation (SCT) has established itself as a very successful therapy in often otherwise unbeatable disorders. In a subset of children and adolescents there are, however, late effects, often as a combination of the underlying disorder, its primary treatment and subsequent SCT. In children and adolescents, disorders of growth and the endocrine system have been observed to occur frequently. The assurance of normal growth, puberty, fertility and thyroid function -including the prevention of secondary malignancies -is of utmost importance for the overall success of treatment and the maintenance of quality of life. This, however, requires a systematic and structured follow-up programme for patients after SCT. Patients and their families need to be made familar with this concept early and physicians need to understand that such a system must be implemented as part of a comprehensive care. Bone Marrow Transplantation (2005) 35, S77-S81.
During the past three decades, stem cell transplantation (SCT) -either autologous or allogeneic -has been established for the treatment of a multitude of formerly untreatable diseases such as errors of the immune system, leukaemia, inborn errors of haematopoiesis and metabolic diseases in children. [1] [2] [3] [4] SCT is the ultimate treatment option after failure of conventional therapies such as chemotherapy, X-ray therapy and surgery in malignant disorders. Currently, however, it is also establishing its role as the primary therapy in a multitude of other disorders such as inborn errors of metabolism. The tremendous success of these treatment forms has led to an increasing number of children and young adults surviving. In fact, it is estimated that currently out of 1000 young adults there is one who has survived SCT.
The survivors who are at the entry of a long life are expecting physical and mental health and the fulfilment of their individual dreams within the private and social setting. It is therefore of utmost importance to identify and cure the potential sequelae of the underlying diseases and the modalities of their cure, and -as an ultimate goalto prevent the late effects of our medical interventions. This goal is obviously difficult to reach given the complexity of the disorders, the variety of developmental stages children and adolescents transgress, the diversity and invasiveness of chemotherapies and X-ray therapies and -not the leastthe different forms of SCT, which are all subjected to a process of development and need to withstand empirical evidence and the test of time. It is obvious that the unique consequences of SCT, a procedure which is embedded into the underlying disorders and the proceeding invasive therapies, cannot always be identified in an individual. The discussion of the late effects after SCT is therefore to the most part also a discussion of the late effects after malignancies in general. However, there are aspects specific for SCT, such as pre-transplantation conditioning by means of total body irradiation (TBI) or chemotherapy, and the chronic graft-versus-host disease with its various organ manifestations. 5 The focus of the article is on the disorders of growth and the endocrine system, which are relatively frequent and play an important role for the developing child as well as for the adult individual. [6] [7] [8] Our own experience in the field is based on the results of the large German-Austrian study, which has been collecting information on more than 400 survivors of SCT in childhood since 1996 9 (Table 1) .
Growth disorders
Statuary growth is in the centre of physical development of children and adolescents. Normal growth and the achievement of the innate growth target require not only nutrition and a normal functioning of supportive tissues such as the gut and the liver, but also the integrity of the growth hormone (GH)-IGF system, a responsive growing tissue and, not the least, a psychologically balanced individual. 10 Aside from the GH-IGF system, other hormonal influences such as thyroid hormones and sex steroids during pubertal development are instrumental. Negative influences of cancer therapy and SCT on the GH-IGF axis have been identified during recent years. 7 X-ray therapy to the hypothalamic-pituitary area has been identified to result in an impairment of GH secretion. Since the threshold dose to this area leading to permanent damage of the GHproducing unit is considered to be at about 18 Gy TBI, irradiation during conditioning for SCT seems not to be the reason for an impaired GH secretion. Since GH effects are partly mediated through IGF-I, which after generation in the liver can act via the endocrine pathway, chronic GvH of the liver is the reason for poor growth. However, recently it has also been recognised that the epiphyseal growth plate can be damaged both by X-rays and chemotherapy. Thus, any growth impairment observed in a child after SCT may be caused by a disturbance at each of these levels of growth regulation or by a quantitatively different contribution of all of these. Owing to the fact that the central regulatory systems and the peripheral organs of the body are interrelated and connected with regulatory loops, difficult diagnostic problems arise whenever poor growth is observed and a pathophysiological explanation is necessary. This is particularly true for cases where the damage of one of the compartments did not completely abolish its function and counter-regulatory mechanisms are still instrumental.
The diagnostic procedures to quantify the functioning of the GH-IGF axis are also complex, partly invasive and not well standardised. There is also hardly any diagnostic access to the functioning of the growing tissue of the growth plate. Therefore, the most sensitive diagnostic procedure for the physician is exact anthropometry, imbedded into clinical investigations, and supported by methods such as bone age rating, defining body composition and, lastly, measuring hormones in various compartments of the body ( Figure 1 ).
In principle, three growth patterns can be observed after SCT: (1) initial poor growth but catch-up after recovery and normal continuation of height development, (2) continuous slowing of height growth, without catch-up and impaired final height and (3) virtually normal growth, but impaired pubertal growth development and subsequently impaired final height. As a rule, growth impairment is more pronounced the younger a child was affected by disease and treatment. [11] [12] [13] Deviations of body proportions and the development of obesity after SCT will need more attention in future. 14 The EBMT Working Party on Late Effects has analysed data on 181 patients with aplastic anaemia, leukaemia and lymphomas, who had BMT before puberty (mean age 9.8 years) and had reached their final height. 12 There was an overall decrease in the final height compared to the relative height at BMT and parental height. Girls had a better outcome. The lower the age at BMT, the greater is the loss in height. Previous cranial irradiation plus single-dose TBI caused the greatest negative effect on final height achievement. Fractionation of TBI or chemical conditioning helps to avoid this negative effect. Importantly, however, 140 of the 181 patients reached a normal adult height. Similar experiences have been published from other large series on height outcome after BMT. 11, 13, 15, 16 Height development in relation to the underlying disorders after SCT in the German-Austrian follow-up programme is illustrated in Figure 2 .
Recently, there has been an ongoing discussion whether or not children with poor growth after SCT (and other malignancies) can be treated efficaciously and safely with recombinant human growth hormone. Undoubtedly, many of these children are treated with GH irrespective of the pathogenic nature of the underlying growth disorder. Analyses from pharmaco-epidemiological studies have also shown that GH does not increase the risk of recurrence of the underlying disorder. 17 Since the responsiveness to GH is, however, reduced compared to, for example, children with idiopathic GHD, higher GH doses have to be applied. The safety of such strategies still needs to be documented.
Thyroid
Thyroid disorders after SCT can occur in terms of functional or structural abnormalities. 18 Structural abnormalities such as of thyroiditis within the frame of GvH disease, or malignancies within the thyroid, tend to be relatively rare events. However, low-dose irradiation to the thyroid has been shown to cause an increased number of neoplasias of the thyroid. 12, 19 Functional disturbances of the thyroid may occur as a result of a damage of the hypothalamic-pituitary unit with an impaired secretion of thyroid-stimulating hormone (TSH) or as a result of an impaired thyroid hormone production within the thyroid, or a combination of both. 20 As a part of the German-Austrian follow-up programme, the thyroid function was evaluated: Before SCT, primary hypothyroidism was observed in 7/269 cases (3%), latent hypothyroidism in 28/269 cases (11%) and secondary hypothyroidism in 18/269 cases (7%). Longitudinal data on 123 patients with a follow-up interval of 36.0 months showed thyroid dysfunction in 42 cases (34%): primary hypothyroidism in two cases (2%), latent hypothyroidism in 32 cases (26%) and secondary hypothyroidism in eight cases (7%). A papillary carcinoma of the thyroid, as a secondary neoplasm, was diagnosed in one patient with a medulloblastoma 7 years after primary treatment and 3 years after SCT. It is noteworthy that abnormalities in thyroid functioning frequently occurred in the follow-up programme after several years of latency 21 ( Figure 3 ). These observations underline that regular functional evaluations (fT4, TSH) before SCT, 6-monthly during the first year and yearly thereafter are required. A morphological evaluation (ultrasound) before SCT and yearly thereafter is also recommended in order to discover structural abnormalities as early as possible. There is some difficulty related to the fact that abnormalities in the thyroid system appear to be quite frequent after SCT, but that they are usually relatively subtle. Thus, there arises the question as to which therapeutical approach has to be made in case of an abnormality such as latent hypothyroidism (ft4 normal -TSH high). We think that the replacement of thyroid hormone is the most practical and safe way in these cases.
Puberty and gonadal function
Puberty, the phase of life when transgression from childhood to a fertile adult occurs, is complex because of the occurring physical changes and the maturational process of the individual. It is still not clear which factors trigger the onset of puberty and why there is a delay of about 2 years in boys compared to girls. In principle, there are signals from the hypothalamus to the pituitary, which by means of the gonadotropins (LH/FSH) stimulate the gonads (ovaries, testes) to grow, to produce germ cells and to secrete sex hormones. It is likely that the size of the body signalled to the central regulatory elements also plays a role in triggering puberty onset. 22 The pre-pubertal status of the child is the result of an active central regulatory process. The changes in body appearance, body composition and height growth are the consequences of the sex hormones produced. Contrary to common belief, pubertal growth (20 cm in girls, 30 cm in boys) is only a relatively small fraction of total height growth.
Disturbances of puberty after SCT can occur as a result of disturbances at the level of the regulatory central unit (hypothalamus, pituitary) or at the level of the gonads. The central unit can be functionally disturbed by X-ray therapy to the scull. 7, 8 High doses will cause impaired gonadotropin secretion, resulting in hypogonadism. Low X-ray doses (o20 Gy), however, may entail an earlier onset of puberty. Early puberty combined with impaired GH secretion are causing severe stunting of growth. The gonads are also damaged by X-ray therapy and chemotherapy. Even low radiation doses of 4 Gy are able to destroy 50% of the oocytes. 23 In particular, alkylating agents such as cyclophosphamide are damaging the male gonads. Germ cells are more affected by cancer therapy including SCT, which is leading to reduced or abolished fertility. Gonadal hormone production is usually less affected. Unfortunately, prepubertal children are no less vulnerable to therapy than pubertal.
The evaluation of pubertal development is quite complex. It is partly based on careful clinical investigations such as anthropometry, staging signs of puberty (genitals (G), breast (B), pubic hair (P)) according to Tanner's classification, measuring testicular size and their consistency in boys, and applying ultrasound technology and documenting the menstrual cycle in girls. In addition, measurements of sex steroids (testosterone, estradiol) and gonadotropins (LH, FSH) may guide to evaluate pubertal development. After an age of about 7 years, elevated basal gonadotropins point to gonadal damage. Central hypogonadism requires a more sophisticated endocrine work-up.
Our own analysis in children after SCT in ALL has shown that in about 80% of these children there is an impairment of gonadal function in boys and girls. 24 In boys the testicles are small. However, testosterone levels are usually retained to a degree allowing the development of pubertal physical characteristics. In girls the visual pubertal development may be adequate, but menstruation is only achieved in half of the individuals and fertility is questioned. 25 Since pubertal development is of utmost importance for the self-esteem and the social integration of adolescents, it must be followed carefully. Replacement of oestrogens and testosterone must be considered if pubertal signs are not occurring after 13 years in girls and after 15 years in boys. Emphatic guidance, in particular with a positive prospect of fertility in the light of new developments, is required. 26 Remarkably, deficits in adrenal functioning (and diabetes mellitus -aside from patients who, based on thalassaemia major, were diabetic at SCT) were rarely recorded.
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Conclusion
After survival of SCT, re-establishment of complete and permanent health and well-being is our main objective. Unfortunately, the underlying disorder, various treatment modalities before SCT and SCT itself may inflict a multitude of health impairments. Disorders of growth, puberty, thyroid and fertility are the most frequent sequelae after childhood SCT. These disorders also reflect the developmental aspects in the aftercare of these patients. Many disorders occur years after SCT and require subtle diagnostic strategies. It is therefore necessary to associate the patients to a long-term follow-up programme. After surviving a life-threatening disease and after the experience of invasive therapies, the patients and their relatives are usually not motivated to participate in follow-up programmes. On the other hand, the diagnosis and correction of late effects are essential for the maintenance of quality of life for the patients. It is therefore important to present a concept of aftercare from early on. This aftercare should avoid all unnecessary burdens and should be adapted to the individuals' needs and situation of life. When provided emphatically and competently, the aftercare for children who have survived SCT is a rewarding task.
